ANDI Andiamo Corporation (CE)

Anadis Ltd. (ASX:ANX; OTC: ANDIY) an Australian biopharmaceutical company announced today the in-licensing of GastroGard-R, an all-natural orally administered formulation containing specific antibodies proven to reduce rotavirus virus diarrhea in young children. The license allows Anadis to exclusively supply humanitarian agencies worldwide as well as to enter large national markets including India, Korea, Indonesia and Australia, with other countries expected to be added based on demand. GastroGard-R is positioned to complement global rotavirus virus vaccine initiatives and reduces overall morbidity and mortality from this terrible disease. The announcement was made at the Partnering for Global Health Forum 2008 (http://pgh.bio.org) being held in Washington D.C. Each year more than 600,000 children die from rotavirus-caused diarrhea and another two million children are hospitalized, predominantly in developing countries (WHO). The virus is spread through exposure to contaminated food and water. Before age five, every child in the world will suffer at least one episode of rotavirus disease, a condition associated with diarrhea, fever and vomiting. The CDC estimates 55,000 children each year in the United States are hospitalized because of rotavirus diarrhea, and that rotavirus is the most common cause of severe diarrhea in children. GastroGard-R provides prophylactic treatment of at -risk children aged one month to three years to prevent diarrhea due to rotavirus. Rotavirus is very infectious in young children and outbreaks occur frequently during winter in hospitals, daycare centers, and in the family setting. Two vaccines have been licensed in the global effort to prevent rotavirus diarrhea related morbidity, Merck�s RotaTeq (NYSE: MRK) and GlaxoSmithKline�s RotaRix (NYSE: GSK) while several global partnerships have been established, involving non-profit agencies, the CDC and the World Health Organization, to reduce the costs of deploying these expensive vaccines. GastroGard-R is positioned to complement vaccine initiatives as part of this worldwide disease control effort. Providing immediate-acting (so-called �passive�) immunity by oral means is especially important for the millions of children without access to these new vaccines, such as children who are too young or old to receive vaccine priority, as well as children at risk from epidemic disease spread in refugee camps, hospitals or daycare centers. GastroGard-R is a non-sterile, oral powder, consisting of the concentrated proteins, including immunoglobulins, from the pre-milk (colostrum) of hyper-immunised cows. The primary immunoglobulin in the formulation is IgG1. GastroGard-R has been studied extensively and has been in use throughout Australia for many years but has not been commercialized globally until now. Six hospital-based clinical studies were performed with GastroGardR, four in Australia and two in other countries. Five of these studies were randomized, double blind, placebo-controlled design and the other study was open. Patients were aged from 28 days to three (3) years and combined analysis of these studies demonstrated a statistically significant reduction in the incidence of rotavirus infection in children given GastroGard-R compared with children not given GastroGard-R� (p